A Baculovirus Dual Expression System-Based Malaria Vaccine Induces Strong Protection againstPlasmodium bergheiSporozoite Challenge in Mice
Authors:
- 1 May 2009
- journal article
- research article
- Published by American Society for Microbiology in Infection and Immunity
- Vol. 77 (5) , 1782-1789
Abstract
We have previously shown that a recombinant baculovirus that displaysPlasmodium bergheicircumsporozoite protein (PbCSP), a homolog of the leading human malaria vaccine candidate, on the viral envelope protected 60% of mice againstP. bergheiinfection. Here, we describe a second-generation baculovirus vaccine based on the “baculovirus dual expression system,” which drives PbCSP expression by a dual promoter that consists of tandemly arranged baculovirus-derived polyhedrin and mammal-derived cytomegalovirus promoters. The baculovirus-based PbCSP vaccine not only displayed PbCSP on the viral envelope but also expressed PbCSP upon transduction of mammalian cells. Immunization with the baculovirus-based PbCSP vaccine elicited high PbCSP-specific antibody titers (predominantly immunoglobulin G1 [IgG1] and IgG2a) and PbCSP-specific CD8+T-cell responses without extraneous immunological adjuvants in mice, indicating that there was induction of both Th1 and Th2 responses (a mixed Th1/Th2 response). Importantly, upon intramuscular inoculation, the baculovirus-based PbCSP vaccine conferred complete protection against sporozoite challenge. Thus, the baculovirus-based PbCSP vaccine induced strong protective immune responses against preerythrocytic parasites. These results introduce a novel concept for the baculovirus dual expression system that functions as both a subunit vaccine and a DNA vaccine and offer a promising new alternative to current human vaccine delivery platforms.Keywords
This publication has 61 references indexed in Scilit:
- Efficacy of RTS,S/AS01E Vaccine against Malaria in Children 5 to 17 Months of AgeNew England Journal of Medicine, 2008
- Memory CD8 T cell responses exceeding a large but definable threshold provide long-term immunity to malariaProceedings of the National Academy of Sciences, 2008
- Phase 2a trial of 0, 1, and 3 month and 0, 7, and 28 day immunization schedules of malaria vaccine RTS,S/AS02 in malaria-naïve adults at the Walter Reed Army Institute of ResearchVaccine, 2008
- Direct Microscopic Quantification of Dynamics of Plasmodium berghei Sporozoite Transmission from Mosquitoes to MiceInfection and Immunity, 2007
- A DNA Prime-Modified Vaccinia Virus Ankara Boost Vaccine Encoding Thrombospondin-Related Adhesion Protein but Not Circumsporozoite Protein Partially Protects Healthy Malaria-Naive Adults against Plasmodium falciparum Sporozoite ChallengeInfection and Immunity, 2006
- DNA Immunization byPlasmodium falciparumLiver-Stage Antigen 3 Induces Protection againstPlasmodium yoeliiSporozoite ChallengeInfection and Immunity, 2001
- Direct Immunization of Malaria DNA Vaccine into the Liver by Gene Gun Protects against Lethal Challenge of Plasmodium berghei SporozoiteBiochemical and Biophysical Research Communications, 2000
- “Baculophage:” A new tool for protein displayBio/Technology, 1995
- Protection against malaria by immunization with a Plasmodium yoelii circumsporozoite protein nucleic acid vaccineVaccine, 1994
- Direct Infection of Hepatocytes by Sporozoites of Plasmodium berghei1The Journal of Protozoology, 1982